supporting the Bayou City's future

$1.5M donation secures new alliance for disaster resilience in Houston

Enbridge and Phillips 66 have made a commitment to making sure Houston has the support it needs to be resilient. Photo via Getty Images

Disaster resilience and recovery efforts in the Houston area are getting a boost.

Thanks to a combined $1.5 million commitment from natural gas company Enbridge and energy company Phillips 66, the Greater Houston Community Foundation, and United Way of Greater Houston have formed the Greater Houston Disaster Alliance.

Enbridge and Phillips 66 are each donating $250,000 annually for three years to finance the alliance. The alliance says it will seek additional funding and partnership opportunities to help ensure the organization’s longevity.

The alliance aims to bolster year-round disaster preparedness in the region. It builds on a partnership worked out two years ago between the foundation and the United Way to coordinate philanthropic responses to Houston-area disasters.

The alliance hasn’t yet named a director. However, it already has begun searching for someone to fill the post, a process that could take several months.

Among the initiatives that the alliance will undertake are:

  • Solidifying infrastructure for directing community-wide philanthropic responses following disasters.
  • Pursuing partnerships with nonprofits to improve disaster relief..
  • Accelerating disaster fundraising and providing seed funding for ongoing resilience and recovery innovations.
  • Establishing a council of public and private leaders to mesh disaster resiliency and recovery strategies.

In the event of a major disaster, the alliance will form a separate leadership council to support fundraising.

“When it comes to disasters, it’s only a matter of time before the Houston region will be impacted again, and the Greater Houston Disaster Alliance gives us the opportunity to take a more proactive and effective approach to disaster recovery and resiliency,” Stephen Maislin, president and CEO of Greater Houston Community Foundation, says in a news release.

Every disaster in the Houston area highlights the struggles faced by residents who already were struggling to meet basic needs, according to Amanda McMillian, president and CEO of the United Way of Greater Houston.

“Recognizing the economic peril that many in our community face when disaster strikes compels us to develop the most effective and equitable social service response that we can now. That is why the work of the Greater Houston Disaster Alliance is so important,” says McMillian.

Houston is certainly no stranger to natural disasters. For example, Hurricane Harvey ranks among the worst U.S. natural catastrophes in the 21st century. The 2017 storm caused an estimated $125 billion in damage in Texas and Louisiana, damaged over 200,000 homes and led to more than 100 deaths.

“Harvey was a wake-up call to all of us who set a course for the city’s future,” Houston Mayor Sylvester Turner said in 2018.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted